Evaluating the safety of Janus kinase inhibitors in the management of severe immune-related adverse events - PubMed
4 hours ago
- #immune-related adverse events
- #Janus kinase inhibitors
- #cancer immunotherapy
- Janus kinase inhibitors (JAKi) are a promising steroid-sparing treatment for severe, corticosteroid-refractory immune-related adverse events (irAEs) caused by immune checkpoint inhibitors (ICIs), but their safety in ICI patients is poorly understood.
- A retrospective multi-institutional study (n=33 JAKi-treated, n=99 corticosteroid-treated controls) and an external validation using TriNetX (n=297 JAKi, n=297 non-JAKi) found no significant difference in overall or progression-free survival between JAKi and control groups.
- Multivariable Cox regression and landmark analyses consistently showed JAKi use was not associated with inferior survival outcomes compared to standard corticosteroid therapy for severe irAEs, with no large adverse safety signals observed.
- The findings suggest JAKi may be safe for managing refractory irAEs without compromising anticancer immunity or ICI response, warranting further investigation in prospective studies.